Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Change in Account Payables: 2019-2024

Historic Change in Account Payables for Foghorn Therapeutics (FHTX) over the last 6 years, with Dec 2024 value amounting to -$2.5 million.

  • Foghorn Therapeutics' Change in Account Payables rose 91.86% to -$110,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$239,000, marking a year-over-year increase of 92.15%. This contributed to the annual value of -$2.5 million for FY2024, which is 392.55% down from last year.
  • Foghorn Therapeutics' Change in Account Payables amounted to -$2.5 million in FY2024, which was down 392.55% from $846,000 recorded in FY2023.
  • In the past 5 years, Foghorn Therapeutics' Change in Account Payables registered a high of $1.6 million during FY2022, and its lowest value of -$2.5 million during FY2024.
  • Moreover, its 3-year median value for Change in Account Payables was $846,000 (2023), whereas its average is -$5,000.
  • In the last 5 years, Foghorn Therapeutics' Change in Account Payables soared by 1,095.56% in 2022 and then tumbled by 392.55% in 2024.
  • Yearly analysis of 5 years shows Foghorn Therapeutics' Change in Account Payables stood at $474,000 in 2020, then crashed by 71.52% to $135,000 in 2021, then soared by 1,095.56% to $1.6 million in 2022, then slumped by 47.58% to $846,000 in 2023, then tumbled by 392.55% to -$2.5 million in 2024.